Effects of Parenteral Nutrition During Chemotherapy on the Immune Functions of Advanced Gastric Cancer Patients
-
摘要:
目的 观察化疗期间肠外营养对中晚期胃癌患者免疫功能的影响。 方法 收集江苏省如皋市人民医院自2008年3月至2010年9月间收治的63例接受化疗的中晚期胃癌患者，随机分为观察组（化疗同时给予肠外营养）36例和对照组（化疗期间未给予肠外营养）27例。观察两组患者化疗疗效、平均化疗周期、无进展生存期，检测化疗前后两组患者营养状况和淋巴细胞亚群情况。 结果 两组患者近期疗效无显著性差异；观察组平均化疗周期和无进展生存期显著优于对照组；化疗后观察组患者营养状况显著优于对照组；淋巴细胞亚群检测显示观察组患者免疫功能得到改善，显著优于对照组。 结论 对中晚期胃癌患者化疗期间给予适当的肠外营养可改善患者的营养状态和免疫功能，患者易于耐受化疗，可取得更好的疗效。 Abstract:Objective To observe the effects of parenteral nutrition during chemotherapy on the immune function of advanced gastric cancer patients. Methods Sixty-three advanced gastric carcinoma patients were admitted to People's Hospital of Rugao City between March 2008 and September 2010. Thirty-six patients in the observation group received parenteral nutrition during chemotherapy, whereas 27 patients in the control group received chemotherapy without parenteral nutrition. The curative effects, average chemotherapy cycles, and progression-free survival were observed. The nutritional states and lymphocyte subclusters of patients were also detected. Results The near-future curative effects of the two groups were not significantly different. However, the average chemotherapy cycle and progression-free survival of the observation group were significantly better than those of the control group. The nutritional states of the patients in the observation group were significantly better after chemotherapy, and their immune functions notably improved compared with those of the control group. Conclusion For advanced gastric cancer patients, parenteral nutrition during chemotherapy can improve their nutrition status and immune functions, enable them more tolerant to chemotherapy and help for achieving better treatment effect. -
Key words:
- Chemotherapy /
- Parenteral nutrition /
- Gastric cancer /
- Immune function
-
表 1 两组患者一般情况的比较 例
Table 1. Comparison of patients' general conditions between the two groups
表 2 两组患者近期化疗疗效的比较 例（%）
Table 2. Comparison of short-term effect of chemotherapy on patients between the two groups
表 3 两组患者化疗疗程及无进展生存期的比较
Table 3. Comparison of the chemotherapy duration and progression free survival of patients between the two groups
表 4 两组患者营养状况的比较
Table 4. The comparison of the nutrition status of patients between the two groups
表 5 两组患者化疗前后免疫功能的改变 %
Table 5. Comparison of patients' immune functions after chemotherapy in the two groups
-
[1] Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer[J]. Br J Cancer, 2010, 102(2): 237-242. doi: 10.1038/sj.bjc.6605380 [2] Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells[J]. Immunol Rev, 2008, 222: 162-179. doi: 10.1111/j.1600-065X.2008.00602.x [3] 陈晓秋, 刘楠楠, 申东兰. 不同术后辅助化疗方案对胃癌患者远期生存的影响[J]. 现代肿瘤医学, 2010, 18(5): 951-953. doi: 10.3969/j.issn.1672-4992.2010.05.40 [4] 罗湘玉, 郭家龙, 左顺庆, 等. 肠外营养添加精氨酸和谷氨酰胺对食管癌术后应激和免疫状态的影响[J]. 肿瘤基础与临床, 2009, 22(1): 73-75. doi: 10.3969/j.issn.1673-5412.2009.01.030 [5] 陈冬生, 张春晓, 田安庆, 等. 奥沙利铂联合卡培他滨治疗晚期胃癌的临床观察[J]. 实用癌症杂志, 2010, 25(2): 167-168. doi: 10.3969/j.issn.1001-5930.2010.02.017 [6] Xiao L, Wang YC, Li WS, et al. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray[J]. J Exp Clin Cancer Res, 2009, 28: 152. doi: 10.1186/1756-9966-28-152 [7] Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis[J]. J Gastroenterol Hepatol, 2009, 24 (4): 646-651. doi: 10.1111/j.1440-1746.2008.05671.x [8] 关志勇, 丁洪斌. 胃癌术后实施肠内营养的合理方案[J]. 齐齐哈尔医学院学报, 2009, 30(4): 423-425. doi: 10.3969/j.issn.1002-1256.2009.04.030 [9] 华军, 薛永生, 吴伟. 肠内营养制剂瑞能对食管癌手术患者的免疫调理[J]. 南京医科大学学报, 2010, 30(11): 1664-1666. [10] 原禄双, 张春颀, 张俊华. 谷氨酰胺联合肠外营养对大肠癌术后恢复的影响[J]. 中国实用医药, 2011, 6(14): 18-19. -
点击查看大图
计量
- 文章访问数: 47
- HTML全文浏览量: 27
- PDF下载量: 1
- 被引次数: 0
下载:
